Treatment of peripheral precocious puberty

Melissa Schoelwer, Erica A. Eugster

Research output: Contribution to journalArticlepeer-review

11 Scopus citations

Abstract

There are many etiologies of peripheral precocious puberty (PPP) with diverse manifestations resulting from exposure to androgens, estrogens, or both. The clinical presentation depends on the underlying process and may be acute or gradual. The primary goals of therapy are to halt pubertal development and restore sex steroids to prepubertal values. Attenuation of linear growth velocity and rate of skeletal maturation in order to maximize height potential are additional considerations for many patients. McCune-Albright syndrome (MAS) and familial male-limited precocious puberty (FMPP) represent rare causes of PPP that arise from activating mutations in GNAS1 and the LH receptor gene, respectively. Several different therapeutic approaches have been investigated for both conditions with variable success. Experience to date suggests that the ideal therapy for precocious puberty secondary to MAS in girls remains elusive. In contrast, while the number of treated patients remains small, several successful therapeutic options for FMPP are available.

Original languageEnglish (US)
Pages (from-to)230-239
Number of pages10
JournalEndocrine Development
Volume29
DOIs
StatePublished - 2016

ASJC Scopus subject areas

  • Pediatrics, Perinatology, and Child Health
  • Endocrinology, Diabetes and Metabolism
  • Endocrinology
  • Endocrine and Autonomic Systems

Fingerprint Dive into the research topics of 'Treatment of peripheral precocious puberty'. Together they form a unique fingerprint.

Cite this